Publish in this journal
Journal Information
Vol. 58. Issue 1.
Pages 66-67 (January - March 2023)
Share
Share
Download PDF
More article options
Visits
...
Vol. 58. Issue 1.
Pages 66-67 (January - March 2023)
Image in cardiology
Full text access
The intrinsic dynamics of fibroelastoma
La dinámica intrínseca del fibroelastoma
Visits
514
Alberto Pozzolia, Francesco Maisanob, Carlos A. Mestresc,
Corresponding author
Carlos.Mestres@usz.ch

Corresponding author.
a Heart Surgery Unit, Cardiocentro Ticino Institute, Lugano, Switzerland
b Heart Surgery Unit, San Raffaele University Hospital, Milan, Italy
c Heart Surgery Unit, Zürich University Hospital, Zürich, Switzerland
This item has received
Article information
Full Text
Download PDF
Statistics
Figures (1)
Additional material (1)
Full Text

Cardiac papillary fibroelastoma has an intrinsic dynamics, which is seldom witnessed. A sea anemone shape response is observed when immersed in normal saline immediately after surgical resection.

Cardiac papillary fibroelastoma (CPF) may arise on any endocardial lined surface and its etiology is mostly associated with injured endocardium. A 83-year-old female patient arrived at our attention after a transient ischemic attack. The transthoracic echocardiography revealed a hyperechogenic mobile structure in the muscular septum, protruding in the left ventricular outflow tract (Fig. 1A), without aortic regurgitation. Computed tomography angiography clearly confirmed it (Fig. 1B).

Fig. 1
(0.1MB).

Through an upper ministernotomy and under cardioplegic arrest, the lesion was resected from the muscular septum. On gross appearance, it offered the morphology of a soft rounded mass, while its dynamics changed when immersed in saline solution. It then assumed the ‘sea anemone’ shape (characteristic non-vascularized ramifications, with an accumulation of collagen fibres endothelium-covered; Fig. 1C, D and video 1 of the supplementary data). After regular discharge of the patient, histopathology confirmed CPF. This dynamic behaviour of CPF may account for its ability to embolize. Written informed consent from the patient was obtained preoperatively for the publication of this case.

Funding

No funding for this study.

Authors’ contributions

The three authors drafted and made equal substantial contributions to the manuscript.

Conflicts of interest

F. Maisano discloses the following: Grant and/or research institutional support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, Terumo. Consulting fees, honoraria personal and institutional from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, Occlufit. Royalty income/IP rights: Edwards Lifesciences. Shareholder (including share options) of Cardiogard, Magenta, SwissVortex, Transseptalsolutions, Occlufit, 4Tech, Perifect. C.A. Mestres discloses the following: Speaker fees Edwards Clinical Events Committee (CEC) and Cytosorbents Corp.

Appendix A
Supplementary data

The following are the supplementary data to this article:

(5.13MB)

Copyright © 2022. Sociedad Española de Cardiología
Idiomas
REC: CardioClinics
Article options
Tools
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?